Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In this trial, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more in patients with high-risk muscle-invasive urothelial carcinoma who had had radical surgery.
Oncology, Medical January 9th 2023
JAMA Network
In this multi-institutional study, AT significantly increased progression-free and overall survival in 430 patients with node-negative (N0) disease after NAT for localized pancreatic cancer (4.1 vs 2.1 and 5.3 vs 3.5 years, respectively). Patients who received neoadjuvant radiation had their overall survival benefit scaled back, while patients with perineural invasion saw an increase.
Oncology, Medical December 5th 2022
Journal of Clinical Oncology
In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.
Oncology, Medical October 3rd 2022
Neurology Advisor
It is well recognized that about 30% of people with epilepsy are resistant to dual drug therapy and that selection of a second or later drug is based more on experience than empirical evidence. Drs. Fields and Marcuse of the Icahn School of Medicine discuss the current status of research and what variables will help guide antileptic selection in resistant cases.
Neurology September 26th 2022
The study was comprised of 17,913 men with a median age of 64 years with pT2-4N1M0 prostate cancer (PC) consecutively treated between 1995 and 2017, with postradical prostatectomy (RP) and pelvic lymph node (LN) assessment. The patients were then followed for possible treatment with adjuvant radiation therapy (aRT) or early salvage radiation therapy (sRT). It was determined that men with pN1 PC and 4 or more as compared with 1-3 positive pelvic LNs appear to benefit the most from the use of aRT.
Oncology, Medical July 18th 2022
Cleveland Clinic Journal of Medicine
This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.
Oncology, Medical July 11th 2022